Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inersan lozenges for chronic periodontitis
NCT01870362Phase 3Completed
- Sponsor
- CD Pharma Group
- Start
- Jun 2013
- Primary completion
- Jul 2014
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
A Phase 3 trial of lactobacillus brevis cd2 in chronic periodontitis, sponsored by CD Pharma Group. Started Jun 2013; status: completed.
02
Drugs
lactobacillus brevis cd2
03
Conditions
chronic periodontitis
Beyond the preview
Go deeper on NCT01870362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01870362.